Pricing Log in Create free account

Trevi Therapeutics, Inc. (TRVI) vs Xencor, Inc. (XNCR)

Trevi Therapeutics, Inc. and Xencor, Inc. are both Biotechnology companies. Trevi Therapeutics, Inc. and Xencor, Inc. are of similar size ($1.8B and $1.7B). Trevi Therapeutics, Inc. has the higher net margin (0.00% vs −155.6%) and the lower return on invested capital (−1,412.1% vs −288.7%). Across the 13 metrics below, Trevi Therapeutics, Inc. leads on 8 and Xencor, Inc. on 5.

Valuation

Metric TRVI XNCR Biotechnology median
P/E n/m n/m 8.50
P/S n/m 16.58 9.71
P/B 5.78 3.46 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales n/m 13.38 9.21
Earnings yield (2.86%) (9.46%) (33.15%)
Free cash flow yield (2.84%) (12.02%) (25.50%)

Profitability

Metric TRVI XNCR Biotechnology median
Gross margin 0.00% 100.00% 65.16%
Operating margin 0.00% (205.84%) 0.00%
Net margin 0.00% (155.59%) 0.00%
Free cash flow margin 0.00% (198.42%) 0.00%
Return on equity (19.66%) (29.07%) (56.36%)
Return on assets (18.97%) (20.36%) (48.04%)
Return on invested capital (1,412.11%) (288.71%) 0.00%

Growth

Metric TRVI XNCR Biotechnology median
Revenue growth (TTM) — (28.56%) 6.02%
EPS growth (last fiscal year) 31.91% 65.36% 30.26%
Revenue growth, 5-year CAGR — 0.47% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric TRVI XNCR Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 37.28 6.39 4.72
Net debt to EBITDA 3.83 2.51 0.96

Dividend

Metric TRVI XNCR Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric TRVI XNCR Biotechnology median
Market cap 1.73b 1.78b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack